Crohn’s disease is diagnosed through a combination of blood tests, stool tests, endoscopy, and imaging, because no single test can confirm it on its own. The process often takes longer than patients expect. One large cohort study found the median time from first symptoms to a formal Crohn’s diagnosis was 20 months, though that gap has been shrinking in recent years as awareness and testing improve.
Why There’s No Single Diagnostic Test
Crohn’s can affect any part of the digestive tract, from the mouth to the anus, and it causes inflammation that extends deep into the bowel wall. That makes it easy to confuse with other conditions, especially irritable bowel syndrome (IBS), infections, or ulcerative colitis. Doctors piece together evidence from your symptoms, lab work, visual inspection of the bowel, and imaging to build a complete picture. The combination of findings is what leads to a diagnosis, not any one result in isolation.
Stool and Blood Tests
The first step is usually lab work. Blood tests check for signs of inflammation (like elevated C-reactive protein) and anemia, which is common when the gut isn’t absorbing nutrients well. These results can raise suspicion but aren’t specific to Crohn’s.
A stool test for a protein called fecal calprotectin is far more useful early on. When your intestines are inflamed, white blood cells release calprotectin into the gut, and it shows up in stool samples. A level below 50 micrograms per gram makes inflammatory bowel disease (IBD) unlikely. In one large analysis, only 2.5% of people with levels below that cutoff turned out to have an organic bowel disease at 12-month follow-up. Levels between 50 and 150 are considered borderline and typically call for monitoring or further testing. The 2025 American College of Gastroenterology guidelines formally endorse a cutoff of 50 to 100 micrograms per gram to separate inflammatory conditions from non-inflammatory ones like IBS.
There are also antibody blood tests that can help distinguish Crohn’s from ulcerative colitis once IBD is suspected. A specific pattern, positive for anti-yeast antibodies (ASCA) and negative for another marker (pANCA), has a pooled specificity of 93% for Crohn’s. That means when this pattern shows up, it’s very likely Crohn’s rather than ulcerative colitis. But the sensitivity is only about 55%, so a negative result doesn’t rule it out. These tests are most helpful in ambiguous cases, particularly in children.
Colonoscopy and Biopsy
Endoscopy remains the gold standard. A colonoscopy with ileoscopy (where the scope reaches the last section of the small intestine) lets a gastroenterologist directly see the lining of the bowel and take tissue samples. Crohn’s has several visual hallmarks that set it apart from other conditions.
The most characteristic finding is “skip lesions,” patches of inflamed, ulcerated tissue separated by stretches of healthy-looking bowel. Ulcerative colitis, by contrast, causes continuous inflammation. Doctors also look for aphthous ulcers (small, shallow sores), deep linear ulcers, and a bumpy texture called cobblestoning, where swollen tissue between crisscrossing ulcers resembles a cobblestone road. Narrowed sections of bowel, called strictures, can also appear.
During the procedure, the doctor takes small tissue samples (biopsies) from multiple sites, including areas that look normal. Under a microscope, pathologists look for features that point specifically to Crohn’s: distorted crypt architecture (the tiny glands lining the intestine become irregular), chronic inflammation concentrated in the deeper tissue layer called the lamina propria, and clusters of immune cells called granulomas. Granulomas are a strong indicator of Crohn’s when present, though they don’t show up in every patient’s biopsy. In severe cases, the inflammation extends through the full thickness of the bowel wall, which is a defining characteristic of Crohn’s that distinguishes it from ulcerative colitis.
Imaging the Small Bowel
A colonoscopy can only reach so far. Since Crohn’s frequently involves the small intestine, which is about 20 feet long and largely inaccessible by scope, imaging plays a critical role. The two primary options are MR enterography (MRE) and CT enterography (CTE). Both require you to drink a large volume of contrast liquid beforehand to distend the bowel and make abnormalities visible.
In terms of diagnostic accuracy, the two are comparable. A meta-analysis found MRE had a sensitivity of 88% and specificity of 87%, while CTE came in at 85% sensitivity and 89% specificity. Neither showed a statistically significant advantage for detecting active disease, fistulas, or strictures. The meaningful difference is radiation: CTE uses X-rays, and because Crohn’s patients are often young and need repeated imaging over a lifetime, accumulated radiation exposure becomes a real concern. MRE uses magnetic fields with no radiation, making it the preferred choice for ongoing monitoring. CTE tends to be faster, more widely available, and less expensive, so it’s still commonly used when MRE isn’t an option or when a quick answer is needed.
The 2025 ACG guidelines also formally endorse intestinal ultrasound as a radiation-free tool for both diagnosis and monitoring. It’s noninvasive and can be done in a clinic visit, making it useful for tracking disease activity between more detailed scans.
Capsule Endoscopy
When colonoscopy and imaging leave questions unanswered, particularly about the middle portions of the small bowel, a capsule endoscopy may be the next step. You swallow a pill-sized camera that takes thousands of pictures as it travels through your digestive tract over about eight hours. It can detect early mucosal changes like small ulcers, cobblestoning, and subtle inflammation that cross-sectional imaging might miss.
The main risk is capsule retention. If Crohn’s has already caused a stricture (a narrowed segment of bowel), the capsule can get stuck. To reduce this risk, doctors sometimes have you swallow a dissolvable “patency capsule” first. If it passes through without problems, the real camera capsule is safe to use. Capsule endoscopy is also useful for distinguishing Crohn’s from ulcerative colitis, since finding disease in the small bowel points strongly toward Crohn’s.
What the Process Looks Like in Practice
If you’re experiencing persistent diarrhea, abdominal pain, weight loss, or blood in your stool, your doctor will likely start with blood work and a fecal calprotectin test. A normal calprotectin level is reassuring and may steer the evaluation toward non-inflammatory causes. An elevated level triggers a referral to a gastroenterologist for colonoscopy.
During colonoscopy, biopsies are taken regardless of what the bowel looks like visually. If the findings suggest Crohn’s, imaging of the small bowel (usually MRE) follows to map the full extent of disease, check for complications like fistulas or abscesses, and assess how deep the inflammation goes. In some cases, capsule endoscopy fills in gaps the scope and imaging couldn’t cover. The entire diagnostic workup, from initial suspicion through confirmed diagnosis, can happen within weeks if referrals move quickly, though historically many patients have waited much longer. Data from a large cohort showed the median diagnostic interval for Crohn’s dropped from 30 months in 2001 to 3 months by 2017, reflecting better recognition of early symptoms and faster access to testing.